To buy or build blockbusters?
A look at blockbuster origins shows the role of external innovation, but more of these huge franchises are in the hands of their inventors than ever before.
Galapagos starts spending Gilead’s cash
A surprise move into the Car-T space suggests the beleaguered Belgian biotech still has an eye on its rich benefactor.
Turning Point and Libtayo steal some pre-Asco thunder
On the eve of Asco two deals show that the current biotech market malaise might be focusing some chief executives’ minds.
GSK goes back to its vaccine bread and butter
But breaking Pfizer and Merck’s duopoly will not be easy.
Diagnostics beat implants in the race to market
Roche had the most innovative approvals over the last five years – but took second place in terms of speed.
Big pharma’s biggest spenders revealed
Bristol Myers Squibb has spent the most on M&A, R&D and licensing since 2017, and Eli Lilly the least. Guess which strategy is working best.
Opportunities arise for once-spurned partners
Following the Pfizer-Biohaven blueprint, could other licensing deals turn into buyouts?
For medtechs seeking deals, it’s hurry up and wait
Last year venture-backed companies waited longer than average for a takeout, and longer than ever for an IPO.
